Study of biomarker profiling to unravel the intertwined pathophysiology of coronary artery disease and abdominal aortic aneurysm

Study of biomarker profiling to unravel the intertwined pathophysiology of coronary artery disease and abdominal aortic aneurysm - BIOMArCS-AAA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53081

Enrollment

440

Registered

2016-12-13

Start date

2017-03-23

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal aortic aneurysm Abdominal aortic aneurysm

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: This study will include: 1. patients with an AAA diameter >=40mm and treated by watchful waiting strategy; 2. patients planned to undergo EVAR; 3. patients who underwent EVAR in past years.

Exclusion criteria

Exclusion criteria: Main exclusion criteria: patients with saccular abdominal aortic aneurysm, isolated iliac artery aneurysm, traumatic aneurysm, anastomotic aneurysm and infectious aneurysm, clinical diagnosed thoracic aneurysm, dialysis dependent patients, women of childbearing age or patients with coexistent condition with life expectancy

Design outcomes

Primary

Measure	Time frame
The primary study endpoint is volume of the aneurysm sac, measured repeatedly by CT scan imaging during 24 months of follow-up.	—

Secondary

Measure	Time frame
Secondary endpoints include maximal diameter and length of the aneurysm, all-cause mortality, quality of life and depression and: - AAA-related adverse events in watchful waiting group: AAA related death, AAA rupture, or any AAA-related intervention. - AAA-related adverse events in EVAR patients: direct (type 1 or 3) or undetermined type endoleaks, migration >10 mm, device integrity failure, AAA-related death, late postimplantation AAA rupture, or any AAA-related secondary intervention. - Cardiovascular events: i.e. cardiovascular death, myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG).	—

Measure

Time frame

Secondary endpoints include maximal diameter and length of the aneurysm, all-cause mortality, quality of life and depression and: - AAA-related adverse events in watchful waiting group: AAA related death, AAA rupture, or any AAA-related intervention. - AAA-related adverse events in EVAR patients: direct (type 1 or 3) or undetermined type endoleaks, migration >10 mm, device integrity failure, AAA-related death, late postimplantation AAA rupture, or any AAA-related secondary intervention. - Cardiovascular events: i.e. cardiovascular death, myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG).

—

Countries

Netherlands

Contacts

Public ContactI Kardys

Erasmus MC, Universitair Medisch Centrum Rotterdam

i.kardys@erasmusmc.nl0650032051

Outcome results